Syros Announces Planned CEO Leadership Transition and Strategic Reorganization
Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies announced a strategic realignment to prioritize key development and pre-launch activities to advance tamibarotene for the frontline treatment of higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML)
Also Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., and the appointment of Conley Chee, Syros’ Chief Commercial Officer (CCO) and Chief Business Officer (CBO), as CEO, effective December 2, 2023. Dr. Simonian will remain a member of the Syros Board of Directors following the transition. As the company prepares to report initial data from SELECT-AML-1 later this year and pivotal data from SELECT-MDS-1 next year, it is increasingly focused on building a robust commercial business that can establish tamibarotene as the foundation of care for patients with RARA gene overexpression.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
